ATE257712T1 - Gesteigerte stimulation der erythropoesis - Google Patents
Gesteigerte stimulation der erythropoesisInfo
- Publication number
- ATE257712T1 ATE257712T1 AT97937379T AT97937379T ATE257712T1 AT E257712 T1 ATE257712 T1 AT E257712T1 AT 97937379 T AT97937379 T AT 97937379T AT 97937379 T AT97937379 T AT 97937379T AT E257712 T1 ATE257712 T1 AT E257712T1
- Authority
- AT
- Austria
- Prior art keywords
- epo
- erythropoiesis
- hemoglobin
- heme
- containing components
- Prior art date
Links
- 230000010437 erythropoiesis Effects 0.000 title abstract 4
- 230000000638 stimulation Effects 0.000 title 1
- 102000001554 Hemoglobins Human genes 0.000 abstract 4
- 108010054147 Hemoglobins Proteins 0.000 abstract 4
- 150000003278 haem Chemical class 0.000 abstract 3
- 102000003951 Erythropoietin Human genes 0.000 abstract 2
- 108090000394 Erythropoietin Proteins 0.000 abstract 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
- 229940105423 erythropoietin Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 abstract 2
- 208000007502 anemia Diseases 0.000 abstract 1
- 230000024245 cell differentiation Effects 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000000267 erythroid cell Anatomy 0.000 abstract 1
- 230000000925 erythroid effect Effects 0.000 abstract 1
- 230000012010 growth Effects 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0641—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/14—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2463296P | 1996-08-27 | 1996-08-27 | |
| PCT/CA1997/000601 WO1998008537A1 (en) | 1996-08-27 | 1997-08-27 | Enhanced stimulation of erythropoiesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE257712T1 true ATE257712T1 (de) | 2004-01-15 |
Family
ID=21821593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97937379T ATE257712T1 (de) | 1996-08-27 | 1997-08-27 | Gesteigerte stimulation der erythropoesis |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20020120098A1 (de) |
| EP (1) | EP0939644B1 (de) |
| JP (1) | JP2002515880A (de) |
| AT (1) | ATE257712T1 (de) |
| AU (1) | AU733714B2 (de) |
| CA (1) | CA2263978A1 (de) |
| DE (1) | DE69727241D1 (de) |
| WO (1) | WO1998008537A1 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0885613A1 (de) | 1997-06-21 | 1998-12-23 | Roche Diagnostics GmbH | Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin |
| NZ508242A (en) | 1998-04-24 | 2003-05-30 | Hemosol Inc | Efficient ex vivo expansion of CD4+ and CD8+ T-Cells from HIV infected subjects |
| WO1999067360A2 (en) * | 1998-06-25 | 1999-12-29 | Hemosol Inc. | Media and methods for expansion of erythroid stem cells for the production of hemoglobin |
| US20030162833A1 (en) | 2001-08-01 | 2003-08-28 | Roe Charles R. | Fatty acid treatment for cardiac patients |
| WO2000045649A1 (en) * | 1999-02-05 | 2000-08-10 | Baylor University Medical Center | Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid |
| DE10002803A1 (de) * | 2000-01-24 | 2001-08-02 | Conbio Lizenzverwertungsgesell | System zur internen qualitativen und quantitativen Validierung von Markerindices |
| US7666615B2 (en) | 2001-01-29 | 2010-02-23 | Hemogenix, Inc. | High-throughput assay of hematopoietic stem and progenitor cell proliferation |
| US7989178B2 (en) | 2001-01-29 | 2011-08-02 | Hemogenix, Inc. | Colony assay miniaturization with enumeration output |
| US7354730B2 (en) * | 2002-01-29 | 2008-04-08 | Hemogenix, Inc. | High-throughput assay of hematopoietic stem and progenitor cell proliferation |
| EP1364197B1 (de) * | 2001-01-29 | 2010-04-14 | Ivan N. Rich | ATP-basierter Assay zur Bestimmung der Proliferation hämatopoetischer Stamm- und Vorläuferzellen |
| DE10215315A1 (de) * | 2002-04-05 | 2003-11-20 | Aventis Behring Gmbh Intellect | Human-Transferrin zur Behandlung der Anaemia of Chronic Disease (ACD) und des funktionellen Eisenmangels |
| DE102004004509B4 (de) * | 2004-01-23 | 2010-07-01 | Epoplus Gmbh Co.Kg | Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden |
| JP2007217283A (ja) * | 2004-03-30 | 2007-08-30 | Niigata Tlo:Kk | 血管新生促進剤および血管新生療法 |
| AU2004319758A1 (en) * | 2004-04-14 | 2005-11-24 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes |
| US7759306B2 (en) | 2006-05-16 | 2010-07-20 | Simoni Jan S | Methods of treating acute blood loss |
| WO2009137836A2 (en) * | 2008-05-09 | 2009-11-12 | Hemogenix, Inc. | Cell potency assay |
| KR101931403B1 (ko) | 2011-09-23 | 2018-12-21 | 블루버드 바이오, 인코포레이티드. | 개선된 유전자 치료 방법 |
| WO2014113593A1 (en) * | 2013-01-18 | 2014-07-24 | Advanced Diagnostic Technologies, Llc | Methods and compositions for preparing blood substitutes |
| CN110548133A (zh) * | 2019-08-30 | 2019-12-10 | 西北大学 | 血红蛋白及血红蛋白衍生物在制备用于提高免疫功能的注射药物制剂方面的用途 |
| CN110531090A (zh) * | 2019-08-30 | 2019-12-03 | 西北大学 | 血红蛋白及血红蛋白衍生物在制备用于抗贫血的注射药物制剂方面的用途 |
| CN114317436A (zh) * | 2021-12-30 | 2022-04-12 | 中国人民解放军军事科学院军事医学研究院 | 一种重新激活人γ-珠蛋白基因表达的方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0441119A3 (en) * | 1990-01-09 | 1992-10-14 | Richard D. Levere | The use of l-arginine in the treatment of hypertension and other vascular disorders |
| WO1992002242A1 (en) * | 1990-07-31 | 1992-02-20 | The Rockefeller University | Use of metalloporphyrins to potentiate aids therapy |
| AU2882992A (en) * | 1991-11-06 | 1993-06-07 | Arthur A. Axelrad | Cell culture medium |
| DK0646130T3 (da) * | 1993-03-16 | 1997-06-02 | Hemosol Inc | Selektiv tværbinding af hæmoglobiner ved hjælp af oxiderede, ringåbnede saccharider |
| CA2106612C (en) * | 1993-09-21 | 2001-02-06 | Diana Pliura | Displacement chromatography process |
| US5545328A (en) * | 1993-09-21 | 1996-08-13 | Hemosol Inc. | Purification of hemoglobin by displacement chromatography |
| US5631219A (en) * | 1994-03-08 | 1997-05-20 | Somatogen, Inc. | Method of stimulating hematopoiesis with hemoglobin |
| US5861483A (en) * | 1996-04-03 | 1999-01-19 | Pro-Neuron, Inc. | Inhibitor of stem cell proliferation and uses thereof |
| US6537777B1 (en) * | 1998-07-27 | 2003-03-25 | Hemebiotech A/S | Human porphobilinogen deaminase sequences |
-
1997
- 1997-08-27 AU AU40065/97A patent/AU733714B2/en not_active Ceased
- 1997-08-27 EP EP97937379A patent/EP0939644B1/de not_active Expired - Lifetime
- 1997-08-27 AT AT97937379T patent/ATE257712T1/de not_active IP Right Cessation
- 1997-08-27 WO PCT/CA1997/000601 patent/WO1998008537A1/en not_active Ceased
- 1997-08-27 CA CA002263978A patent/CA2263978A1/en not_active Abandoned
- 1997-08-27 JP JP51111698A patent/JP2002515880A/ja active Pending
- 1997-08-27 DE DE69727241T patent/DE69727241D1/de not_active Expired - Lifetime
-
2001
- 2001-10-09 US US09/985,218 patent/US20020120098A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP0939644B1 (de) | 2004-01-14 |
| CA2263978A1 (en) | 1998-03-05 |
| AU4006597A (en) | 1998-03-19 |
| DE69727241D1 (de) | 2004-02-19 |
| JP2002515880A (ja) | 2002-05-28 |
| EP0939644A1 (de) | 1999-09-08 |
| US20020120098A1 (en) | 2002-08-29 |
| AU733714B2 (en) | 2001-05-24 |
| WO1998008537A1 (en) | 1998-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69727241D1 (de) | Gesteigerte stimulation der erythropoesis | |
| US5091171B2 (en) | Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use | |
| IL138723A (en) | Composition containing cisplatin and stilbene for treatment of tumors | |
| BR9913319A (pt) | Composições e métodos para tratamento de doenças mitocondriais | |
| ATE259215T1 (de) | Zusammensetzung zur regulierung des hauterscheinungsbildes | |
| NZ326874A (en) | 6-phenylpyridyl-2-amine derivatives | |
| AU2118488A (en) | Improvements in or relating to methods of treating damaged skin | |
| MY121294A (en) | Novel hexanoic acid derivatives. | |
| AU6414994A (en) | Composition and method for reducing toxicity of biologically-active factors | |
| IL104006A0 (en) | Azaheterocyclylmethyl-chromans,their preparation and pharmaceutical compositions containing them | |
| WO2002038171A3 (en) | METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF α-L-IDURONIDASE | |
| GR3005608T3 (de) | ||
| AU6567086A (en) | Compositions and methods for the treatment of bleeding disorders | |
| CA2388939A1 (en) | Therapeutic treatments for blood cell deficiencies | |
| EP0506658A4 (en) | Compositions and method for treating painful, inflammatory or allergic disorders | |
| BR9500436A (pt) | Produtos uso de um g-csf uso de uma proteína tnf ligante processo para o tratamento e/ou prevenção do choque séptico | |
| ES2106531T3 (es) | Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso. | |
| AU587054B2 (en) | Novel pharmaceutical compositions intended to the treatment of neuropathies and insuring the nervous regeneration | |
| AU6178198A (en) | Method of treating a tumor | |
| ZA957507B (en) | L-carnitine salt and cosmetic and pharmaceutical compositions containing same for treating dermatoses | |
| IE861148L (en) | Compound for treating bone disorders | |
| IL126235A (en) | Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use | |
| CA2108330A1 (en) | Enhancer for the Antianemia Effect of Erythropoietin and Method of Augmenting the Antianemia Effect of Erythropoietin | |
| WO1999055861A3 (en) | Fibroblast growth factor mutein compositions and methods of use therefor | |
| WO2002005801A3 (en) | Compositions containing diacyltartaric salts of (e)-metanicotine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |